Clinical utility of PSMA PET in prostate cancer
Research type
Research Study
Full title
What is the clinical utility of Positron Emission Tomography (PET) with Prostate Specific Membrane Antigen (PSMA) ligands in patients with prostate cancer?
IRAS ID
261580
Contact name
Jamshed Bomanji
Contact email
Sponsor organisation
University College London
Clinicaltrials.gov Identifier
Z6364106/2020/07/134, Data Protection Registration Number
Duration of Study in the UK
4 years, 11 months, 30 days
Research summary
Imaging with radiolabeled Prostate Specific Membrane Antigen (PSMA) Positron Emmission Tomography(PET)has been reported as a promising diagnostic tool for the assessment of patients with prostate cancer in various stages of the disease. However, the method needs further evaluation, before this modality enters mainstream and routine clinical use. This study will analyse data of patients with prostate cancer who underwent PSMA PET at the Institute of Nuclear Medicine in University College London Hospitals (UCLH)as part of clinical workup for primary staging, follow-up, recurrence or response assessment to treatment. The goals are to evaluate the efficacy of the method, compare the results with those of histopathology and standard-of-care imaging (e.g. bone scan, CT or magnetic resonance imaging), serum markers of disease (prostate specific membrane antigen) and assess the impact on clinical management choices, in order to identify the patients that are more likely to benefit from PSMA PET imaging. Secondary goals of the study include evaluation of different protocols/tracers and identification of issues that could arise from observer-related variability or potential pitfalls in image interpretation.
REC name
North East - Newcastle & North Tyneside 2 Research Ethics Committee
REC reference
20/NE/0236
Date of REC Opinion
10 Nov 2020
REC opinion
Further Information Favourable Opinion